Menu Search
Equities

Braxia Scientific Corp

BRAXF:PKC

Braxia Scientific Corp

Actions
  • Price (USD)0.0064
  • Today's Change0.000 / 1.59%
  • Shares traded148.63k
  • 1 Year change-61.21%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 20:36 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Braxia Scientific Corp. is a Canada-based company, which is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing drugs and delivery methods. The Company seeks to develop ketamine and derivatives and other psychedelic products from its Internet protocol (IP) development platform. The Company has clinic operations in the Canadian cities of Mississauga, Toronto, Kitchener-Waterloo, Ottawa and Montreal. The Company, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., it operates multidisciplinary community-based clinics offering rapid-acting treatments for depression located in Mississauga, Toronto, Ottawa, Kitchener and Montreal. Its subsidiaries include Altmed Capital Corp., Artisan Growers Ltd., KetaMD, Inc., Novo Formulations Ltd. and Tassili Life Sciences Corp.

  • Revenue in CAD (TTM)2.21m
  • Net income in CAD-9.64m
  • Incorporated2019
  • Employees--
  • Location
    Braxia Scientific Corp2300 - 1177 West Hastings StreetVANCOUVER V6E2K3CanadaCAN
  • Phone+1 (604) 525-9409
  • Websitehttps://braxiascientific.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.